Competency Assessment: Diagnostic Methods for Detection of Cryptosporidium, Microsporidia, and Toxoplasma in Bronchoalveolar Lavage Samples

Zahra Eslamirad 1, Abdolatif Moini 2, Mojtaba Didehdar 3, Reza Hajihossein 1 and Ali Arash Anoushiravani 3, *

1Department of Medical Parasitology and Mycology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
2Department of Internal Medicine, Amir-al Momenin Hospital, Arak University of Medical Sciences, Arak, Iran
3Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
*Corresponding author: Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Email: anoush_aa@yahoo.com

Received 2020 November 09; Revised 2021 March 17; Accepted 2021 March 17.

Abstract

Background: Protozoa have the ability to replace the human lung. Over recent years, the incidence of pulmonary infections caused by these microorganisms has increased, particularly in individuals with an immunodeficiency. The use of appropriate diagnostic methods is particularly important in the identification of parasites in pulmonary secretions.

Objectives: The present study aimed to evaluate and compare PCR-based diagnostic methods with the gold standard method to detect three pathogenic protozoa, including Toxoplasma, Cryptosporidium, and Microsporidia in bronchoalveolar lavage (BAL) samples obtained from immunocompromised patients with chronic obstructive pulmonary disease.

Methods: A BAL sample of immunodeficient patients suffering from chronic obstructive pulmonary disease (COPD) was examined by direct microscopy and PCR methods.

Results: In this study, we examined 64 patients with immunodeficiency accompanied by COPD. Microsporidia were not identified in the samples. Direct methods identified three and nine cases of Toxoplasma and Cryptosporidium, respectively. However, the molecular method identified two and two cases of pulmonary infection with these parasites.

Conclusions: Determining the standard diagnostic method for parasites is dependent on factors, such as the type of specimen and the type of parasite. Based on the results of the present study, the direct microscopic method is the optimal diagnostic method for Toxoplasma and Cryptosporidium in BAL samples.

Keywords: Bronchoalveolar Lavage (BAL), Immunocompromised Patient, Cryptosporidium, Chronic Obstructive Pulmonary Disease (COPD), Toxoplasma

1. Background

The potential of protozoan parasites for entry and replacement in the human lung has been reported in some studies (1, 2). Up to now, few cases of respiratory infections caused by parasites have been reported, which may be attributed to the difficulty associated with detecting parasitic agents in respiratory specimens. However, over recent years, there has been an increase in the reports of lung infections caused by parasites (3-5). Most parasitic lung infections are asymptomatic, but it has been reported that if the immune system is weakened, these infections can be accompanied by symptoms (1, 2). The most prevalent parasites causing lung infections are Toxoplasma, Cryptosporidium, and sometimes Acanthamoeba and Microsporidia (1, 2).

Researchers have studied the effectiveness of several diagnostic methods for identifying these parasites. For instance, Niyyati et al. (6), Perez-Santonja et al. (7), and Boggild et al. (8) evaluated and compared different diagnostic methods for identifying Acanthamoeba keratitis. Saigal et al. (9) and Khanaliha et al. (10) assessed the direct microscopic and molecular methods for the identification of Microsporidia in fecal samples, and Ozkoc et al. (3) compared the same methods for the identification of the same parasite in bronchoalveolar lavage (BAL) samples.

Mercado et al. (11) compared the potential of the Ziehl Neelsen and molecular methods in the detection of Cryptosporidium in sputum samples. Bourdin et al. (12) investigated the potential of molecular and immunoblotting...
methods in the diagnosis of *Toxoplasma* in blood and ocular specimens of patients with ocular toxoplasmosis and compared them with the control group. Lavrard et al. (13) compared the efficiency of three diagnostic methods to detect pulmonary toxoplasmosis in BAL samples. To identify infectious agents in the lung, the appropriate sample is generally the secretion of the lower respiratory tract obtained through the BAL technique (14, 15). Various methods have also been used to identify parasites in lung specimens (2, 3). However, the value of these methods in detecting these parasites is yet to be elucidated in BAL specimens.

### 2. Objectives

In our country, studies on respiratory parasitic infections are scarce and far between. The present study aimed to evaluate and compare two diagnostic methods to detect some pathogenic protozoa in BAL samples obtained from immunocompromised patients with chronic obstructive pulmonary disease (COPD).

### 3. Methods

#### 3.1. Sampling

Our study population included those who had both impairments of the immune system and respiratory disorders, approved by specialists. We excluded people who had no respiratory symptoms and people whose impairment of the immune system was not approved.

#### 3.2. Respiratory Secretion Preparation

Written informed consent was obtained from the selected patients, and they completed a questionnaire containing the demographic information and the history of background disease. The pulmonary secretions of each patient were then obtained by the BAL technique (16). Fresh samples were immediately transferred to the laboratory, and the testing process was initiated on them.

#### 3.3. Experiments

##### 3.3.1. Direct Microscopic Diagnosis

Two smears were provided from each sample and stained by Ziehl Neelsen and Giemsa methods for direct microscopic diagnosis. The Ziehl-Neelsen stained smears were used to diagnose *Cryptosporidium* (1) and *Microsporidia* (17). The Giemsa stained smears were used to diagnose *Toxoplasma* (18).

##### 3.3.2. PCR

The remaining samples were used for the PCR assay to diagnose the three protozoan parasites. First, the DNA was extracted by the phenol-chloroform method (19). Afterward, the genus-specific primers of four kinds of protozoa were used for PCR amplification. Table 1 presents the sequences of specific primers to diagnose the parasites. A Master Mix kit (CinnaGen Co.) was used to optimize the PCR assays. A final volume of 25 µL was used for amplification in an Eppendorf thermocycler (Eppendorf AG, Germany). The programs were used according to the following table (Table 2). Finally, the PCR products were assessed by 1.5% agarose under ultraviolet light. Of note, the positive control of *Cryptosporidium* and *Microsporidia* was kindly awarded by Dr. Majid Pirestani (Parasitology and Entomology Department, Tarbiat Modares University, Tehran, Iran), and *Toxoplasma* was provided by Dr. Saeedeh Shojaee (Department of Parasitology, Tehran University of Medical Sciences, Tehran, Iran).

##### 3.3.3. Sensitivity and Specificity Assessment

The sensitivity and specificity of the PCR-based diagnostic method were separately calculated and compared with the standard gold method of each parasite.

### 4. Results

In this study, we examined 64 patients with immunodeficiency accompanied by COPD. Table 3 presents the results of the examination of BAL specimens with direct and PCR methods to identify *Toxoplasma*, *Cryptosporidium*, and *Microsporidia* parasites. Noteworthy, *Microsporidia* was not identified in the samples using these two diagnostic methods.

The sensitivity and specificity of the PCR-based method compared to the gold standard method for *Toxoplasma* and *Cryptosporidium* are summarized in Table 4. As observed, the sensitivity and specificity of the PCR-based method were 66.7% and 100% for *Toxoplasma* and 11.1% and 98.2% for *Cryptosporidium*.

### 5. Discussion

The increase in the identification of various immune system disorders worldwide has revealed the incidence of more disseminated parasitic infections, such as pulmonary infections (24-26). These infections require special attention because significantly more immunocompromised cases have been reported in recent years (1). Misi-
diagnosis of these infections can lead to treatment failure and death (1). In this regard, the standardization of differential diagnostic methods seems to be the first step for identifying the types of parasites that cause respiratory infections. Today, there are facilities for direct microscopic examination (staining), and there exist culture and PCR-based methods for identifying different types of parasites (27). These methods are routinely used for the laboratory detection of COPD causative agents in the samples of pulmonary secretions (28). The efficiency of a diagnostic method may change based on the type of specimen; therefore, it is necessary to design and conduct studies to evaluate the effectiveness of various techniques for different types of specimens, like the current study.

In the present study, all BAL samples were examined by two methods to compare the sensitivity and specificity of each method for identifying different kinds of protozoa. Our observations showed that the sensitivity of PCR for identifying Toxoplasma and Cryptosporidium was 66.7% and 11.1%, respectively (Figure 1). Furthermore, Microsporidia was not detected in BAL samples by PCR and direct microscopic methods. In a study, Lavrard et al. (13) analyzed BAL samples from HIV patients for Toxoplasma infection. The researcher did not report any difference in the efficiency of direct microscopic and PCR methods in identifying this parasite, which is contrary to the present study, where the direct method was more sensitive.

Due to the similarity of the specimens and the diagnostic method in both studies, it seems that a human er-

| Parasites          | Size of Fragments, bp | Specific Primers                  |
|--------------------|-----------------------|-----------------------------------|
| Toxoplasma (20)    | ~ 529                 | 5’CGCTGACGGAGAAAGCGAAGTTG3’       |
|                    |                       | 5’GGCTGACGACCGCACTGTGCATT3’       |
| Cryptosporidium (21, 22) | ~ 1325               | 5’TTCAGAGCTAATACATGCG3’          |
|                    |                       | 5’CCCTAATCTCCGAAACAGGAA3’        |
| Microsporidia (21) | ~ 250-279             | 5’CACCAGGTGATTCTGCGCGG3’          |
|                    |                       | 5’CCCTCGGAAACCCCTCGT3’           |

| Parasite          | Initial Denaturing Temperature (Time) | Number of Amplification Cycles | Denaturing Temperature (Time) | Annealing Temperature (Time) | Extension Temperature (Time) | Final Extension Temperature (Time) |
|-------------------|---------------------------------------|-------------------------------|-------------------------------|-----------------------------|-------------------------------|-----------------------------------|
| Toxoplasma        | 94°C (5 min)                          | 35                            | 94°C (30 s)                   | 58°C (30 s)                 | 72°C (30 s)                   | 72°C (10 min)                    |
| Cryptosporidium   | 94°C (5 min)                          | 32                            | 94°C (45 s)                   | 55°C (40 s)                 | 72°C (60 s)                   | 72°C (7 min)                     |
| Microsporidia     | 94°C (10 min)                         | 35                            | 94°C (30 s)                   | 62°C (30 s)                 | 72°C (30 s)                   | 72°C (10 min)                    |

| Parasite          | Positive | Negative | Total | Positive | Negative | Total |
|-------------------|----------|----------|-------|----------|----------|-------|
| Direct Method (Gold Standard) |          |          |       |          |          |       |
| PCR (Toxoplasma)  |          |          |       |          |          |       |
| Positive          | 2        | 0        | 2     | 2        | 0        | 2     |
| Negative          | 1        | 61       | 62    | 1        | 61       | 62    |
| Total             | 3        | 61       | 64    | 3        | 61       | 64    |
| PCR (Cryptosporidium) |        |          |     |          |          |       |
| Positive          | 1        | 1        | 2     | 1        | 1        | 2     |
| Negative          | 8        | 54       | 62    | 8        | 54       | 62    |
| Total             | 9        | 55       | 64    | 9        | 55       | 64    |

Table 1. Characteristics of the Primers Used in the Present Study

Table 2. The PCR Amplification Program for Each Protozoan

Table 3. Frequency of Three Parasitic Protozoa in Patients with Immunodeficiency Accompanied by COPD Based on Direct and PCR Methods

Table 4. Sensitivity and Specificity of the PCR Method Compared to the Gold Standard (Direct Method) for Toxoplasma and Cryptosporidium in BAL Samples of Immunocompromised Patients

Jundishapur J Microbiol. 2020; 13(12):e111038.
ror led to the difference in the results. In another study, Morgan et al. assessed the potential of PCR and direct microscopic method (acid-fast staining) to identify *Cryptosporidium* in fecal samples. In contrast to our study, they showed that compared with routine microscopic methods, the PCR method was more efficient in identifying *Cryptosporidium* in this type of specimen (29). However, in a review study of respiratory cryptosporidiosis, Sponseller et al. (30) reached a conclusion similar to ours. More specifically, they reported that the direct microscopic methods (acid-fast and Giemsa) were more efficient than PCR in identifying *Cryptosporidium* in BAL samples. It seems that the difference between the samples (stool and BAL) led to the difference between the results of the present study and Morgan et al.’s study (29).

Recent studies have confirmed that PCR is an accurate method for identifying and determining *Cryptosporidium* species. Nonetheless, when the number of parasites is low, they cannot be detected by PCR. Primers also play a role in the sensitivity and specificity of the test. The newly designed primers seem to be effective in detecting a small number of *Cryptosporidium* parasites in fecal specimens (31). However, for more accurate conclusions, these primers should be tested on other samples, as well.

Saigal et al. (9) and Mena et al. (32) evaluated the direct microscopic and nested PCR methods in the detection of intestinal microsporidiosis. In their study, the sensitivity and specificity of the molecular method were reported to be higher than those of the staining methods. In both studies, two staining methods were compared to detect *Microsporidia*. Based on the results, the modified trichrome staining had more sensitivity and specificity compared to the calcifluor staining method. Ozkoc et al. (3) and Tabatabaie et al. (31) conducted a similar study on BAL samples and obtained similar results to the previous study. In our study, *Microsporidia* was not detected in any specimen. In Iran, the prevalence of *Microsporidia* in immunocompromised patients was 8.18% (34). Given that the gastrointestinal and pulmonary cases of *Microsporidia* are most often reported in immunocompromised individuals, it is possible that the result of our study was false-negative. Differences in the type of specimens, incorrect choice of staining method, and factors such as DNA extraction and examiner experience (in identifying *Microsporidia*) can be effective in obtaining such results.

5.1. Conclusions

Determining a standard diagnostic method for parasites depends on factors, such as the type of specimen and the type of parasite. Based on the results of the present study, the direct microscopic method is the best diagnostic method for *Toxoplasma* and *Cryptosporidium* in BAL samples. There was only a slight difference between the results of direct microscopic examination and PCR in the diagnosis of *Toxoplasma*; therefore, to achieve more accurate results, it is suggested that such studies be repeated with larger sample sizes and different specimen types.

Acknowledgments

The authors would like to thank the Research Deputy of Arak University of Medical Sciences for financial support of this research (code: 2723).

Footnotes

**Authors’ Contribution:** Study concept and design: Zahra Eslamirad, Mojtaba Didehdar, and Ali Arash Anoushiravani. Screening and selecting the patients: Abdolatif Moini and Ali Arash Anoushiravani. Sampling: Abdolatif Moini and Mojtaba Didehdar. Performing the experiments and analysis of data: Zahra Eslamirad and Reza Hajihossein. Drafting of the manuscript: Zahra Eslamirad and Ali Arash Anoushiravani. Revising the manuscript: Zahra Eslamirad.

**Conflict of Interests:** The authors declare that there is no conflict of interest in this study.

**Ethical Approval:** This research project was approved by the Ethics Committee of Arak University of Medical Sciences (code: IR.REC.1395.347).

**Funding/Support:** This study was supported by the Research Deputy of Arak University of Medical Sciences.

**Informed Consent:** Informed consent was obtained from all individual participants included in the study. Each participant was given a fair idea of the study, and informed consent was obtained from all 64 patients with immunodeficiency accompanied by COPD, emphasizing the fact that they could refuse participation or leave the study at any time, without adverse effects on treatment. Participation was voluntary. At the time of the interview and clinical examination, privacy was maintained, and data collected were kept confidential for ethical issues.
Figure 1. Identification of *Toxoplasma* and *Cryptosporidium*. A, *Toxoplasma* tachyzoites in the BAL sample by staining method (Giemsa staining, 100×); B, *Toxoplasma* identification by PCR method [Lane 1, marker (thermo-scientific SM0313); Lane 2, positive control; Lane 3, negative control; Lanes 4-6, positive samples with specific fragment for *Toxoplasma* (~529 bp)]; C, *Cryptosporidium* oocysts in the BAL sample by staining method (Ziehl Neelsen staining, x100); D: *Cryptosporidium* identification by PCR method [Lane 1, marker (thermo-scientific SM0313); Lane 2, negative control; Lane 3, positive control; Lane 4, positive sample with specific fragment for *Cryptosporidium* (~1325 bp)].

References

1. Martinez-Giron R, Esteban JG, Ribas A, Doganci L. Protozoa in respiratory pathology: A review. *Eur Respir J*. 2008;32(5):1354–70. doi: 10.1183/09031936.00022008. [PubMed: 18978156].

2. Cheepsattayakorn A, Cheepsattayakorn R. Parasitic pneumo-nia and lung involvement. *Biomed Res Int*. 2014;2014:874021. doi: 10.1155/2014/874021. [PubMed: 24995312]. [PubMed Central: PMC4068046].

3. Ozkoc S, Bayram Delibas S, Akisu C. Evaluation of pulmonary microsporidiosis in iatrogenically immunosuppressed patients. *Tuberk Toraks*. 2016;64(1):9-16. doi: 10.5578/tt.10207. [PubMed: 27266280].

4. Petersen E, Edvinsson B, Lundgren B, Benfield T, Evengard B. Diagnosis of pulmonary infection with *Toxoplasma gondii* in immunocompromised HIV-positive patients by real-time PCR. *Eur J Clin Microbiol Infect Dis*. 2006;25(6):401–4. doi: 10.1007/s10096-006-0156-5. [PubMed: 16787490].

5. Poirot JL, Deluol AM, Antoine M, Heyer F, Cadranel J, Meynard JL, et al. Broncho-pulmonary cryptosporidiosis in four HIV-infected patients. *Jubilé torax*. 2006:25(6):401-4. doi: 10.1007/s10096-006-0156-5. [PubMed: 16787490].

6. Niyyati M, Lorenzo-Morales J, Mohebali M, Rezaeian M. Comparison of three staining methods for the detection of intestinal Microspora spp. *Iran J Parasitol*. 2014;9(4):445–51. [PubMed: 2575924]. [PubMed Central: PMC4345082].

7. Lavrard I, Chouaid C, Roux P, Poirot JL, Marteau M, Lemarchand B, et al. Pulmonary toxoplasmosis in HIV-infected patients: Usefulness of polymerase chain reaction and cell culture. *Eur Respir J*. 1995;8(5):697-700. [PubMed: 7544741].
20. Homan WL, Vercammen M, De Braekeleer J, Verschueren H. Identification and genotyping of Cryptosporidium and intestinal Microsporidia in HIV/AIDS patients with primary immunodeficiency disease. J Gen Virol. 2020;101(9):2303-12. doi: 10.1099/jgv.0.001708-0. [PubMed: 3218271]. [PubMed Central: PMC7063407].

21. Yu JR, Lee SU, Park WY. Comparative sensitivity of PCR primer sets for detection of Cryptosporidium parvum. Korean J Parasitol. 2009;47(3):293-7. doi: 10.3347/kjp.2009.47.3.293. [PubMed: 19724705]. [PubMed Central: PMC375697].

22. Ghorbazadeh B, Sadrzadeh J, Emadi Kuchak H. Diagnosis of Cryptosporidium and intestinal Microsporidia in HIV/AIDS patients with staining and PCR methods on 16S rRNA gene. J Arak Univ Med Sci. 2012;15(7):37-47.

23. Pilania RK, Chaudhary H, Jindal AK, Rawat A, Singh S. Current status and prospects of primary immunodeficiency diseases in Asia. Genes Dis. 2020;7(1):3-11. doi: 10.1016/j.jgendi.2019.09.004. [PubMed: 3218271]. [PubMed Central: PMC7063407].